Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers

Conditions: Prostate Cancer Interventions: Drug: Darolutamide; Drug: Darolutamide matched placebo; Radiation: Radiotherapy; Drug: Zoladex 3.6Mg Implant; Drug: Zoladex LA; Drug: Decapeptyl sustained release 22.5 mg; Drug: Decapeptyl sustained release 11.25 mg; Drug: Depo-Eligard 45 mg; Drug: Depo-Eligard 22.5 mg; Drug: Depo-Eligard 7.5 mg; Drug: Firmagon 120 MG Injection; Drug: Firmagon 80 MG Injection; Drug: Docetaxel Sponsors: Cancer Research Antwerp; Bayer; Veracyte, Inc. Recruiting

https://clinicaltrials.gov/study/NCT06282588

Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials